Capital Fund Management S.A. Grows Position in The Chemours Company (NYSE:CC)

Capital Fund Management S.A. increased its stake in The Chemours Company (NYSE:CC - Free Report) by 14.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 181,579 shares of the specialty chemicals company's stock after acquiring an additional 22,901 shares during the quarter. Capital Fund Management S.A. owned 0.12% of Chemours worth $3,069,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. HighTower Advisors LLC lifted its holdings in shares of Chemours by 10.1% in the 3rd quarter. HighTower Advisors LLC now owns 15,020 shares of the specialty chemicals company's stock worth $300,000 after purchasing an additional 1,384 shares in the last quarter. Barclays PLC increased its holdings in Chemours by 28.4% during the 3rd quarter. Barclays PLC now owns 107,549 shares of the specialty chemicals company's stock worth $2,185,000 after purchasing an additional 23,766 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Chemours by 1.2% in the third quarter. Geode Capital Management LLC now owns 2,491,748 shares of the specialty chemicals company's stock valued at $50,646,000 after purchasing an additional 28,803 shares in the last quarter. M&T Bank Corp boosted its position in shares of Chemours by 4.1% during the third quarter. M&T Bank Corp now owns 510,343 shares of the specialty chemicals company's stock valued at $10,370,000 after buying an additional 20,122 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after buying an additional 765 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Trading Up 3.1 %

Shares of NYSE CC traded up $0.35 during mid-day trading on Friday, hitting $11.37. The stock had a trading volume of 1,640,388 shares, compared to its average volume of 1,838,233. The business has a 50 day moving average price of $13.83 and a two-hundred day moving average price of $17.30. The Chemours Company has a 1 year low of $9.33 and a 1 year high of $29.21. The firm has a market cap of $1.70 billion, a P/E ratio of 19.94 and a beta of 1.84. The company has a debt-to-equity ratio of 6.70, a quick ratio of 0.92 and a current ratio of 1.68.

Chemours (NYSE:CC - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The business had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. On average, equities analysts anticipate that The Chemours Company will post 2.03 EPS for the current fiscal year.

Chemours Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 8.80%. Chemours's dividend payout ratio is currently 175.44%.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Morgan Stanley dropped their price objective on Chemours from $25.00 to $22.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Mizuho set a $15.00 price target on shares of Chemours in a report on Tuesday, April 15th. The Goldman Sachs Group decreased their price objective on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating for the company in a research note on Tuesday, January 7th. BMO Capital Markets cut their target price on Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research note on Wednesday, February 19th. Finally, Truist Financial decreased their price target on Chemours from $27.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 14th. Four analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Chemours currently has an average rating of "Moderate Buy" and a consensus target price of $21.56.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.